NRx Pharmaceuticals, Inc.
NRXP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $23 | $35 | $730 | $2,243 |
| - Cash | $1 | $5 | $20 | $28 |
| + Debt | $7 | $9 | $11 | $1 |
| Enterprise Value | $28 | $39 | $720 | $2,216 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| EBITDA | -$24 | -$30 | -$40 | -$93 |
| % Margin | – | – | – | – |
| Net Income | -$25 | -$30 | -$40 | -$93 |
| % Margin | – | – | – | – |
| EPS Diluted | -2.39 | -3.98 | -0.6 | -7.44 |
| % Growth | 39.9% | -563.3% | 91.9% | – |
| Operating Cash Flow | -$11 | -$22 | -$40 | -$38 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$11 | -$22 | -$40 | -$38 |